Ascletis Inc., a Chinese biotech specializing in liver disease treatments with a focus on hepatitis C, has completed a major $100m Series B financing, following a first round $55m fundraising in the second half of 2015.
The second round was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
